Skip navigation

Chris Christoffersen, Ph.D.
General Partner

Chris is a General Partner of Lightstone Ventures. He focuses on biopharmaceutical investments out of the firm’s Boulder, CO, office. Chris joined Morgenthaler in 2001 and serves as a General Partner. His signature deals include Avidia (acquired by Amgen in 2006), Threshold (NASDAQ: THLD), Morphotek (acquired by Easai in 2007), FoldRx (acquired by Pfizer in 2010), and Nimbus Therapeutics/Apollo (acquired by Gilead in 2015). He serves on the boards of Tragara Pharmaceuticals, Asterand, Elcelyx, and Nimbus. Chris brings to Lightstone more than 20 years of operations experience, having served as CEO and President of Ribozyme Pharmaceuticals (a/k/a Sirna Therapeutics; acquired by Merck for $1.2B), Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.

Chris is a recognized thought leader in the field of biotechnology. He received an honorary doctor of law degree from Cornell College in 1983, the Outstanding Research of Year Award from the International Society of Quantum Biology in 1981, the W. E. Upjohn Award for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association.

Education: 

B.S. in Chemistry and Mathematics, Honorary J.D. from Cornell College
Ph.D. in Chemistry from Indiana University

News

  • 06.02.17
    Gormley’s Take: Punching Back at Liver Cancer

    Efforts to conquer the growing threat of liver cancer haven’t benefited much...

  • 05.05.17
    Gormley’s Take: Nimbus’s Evolving Model One to Watch for Biotech VCs

    Investors seek strategies for generating maximum value from biotech startups...

  • 04.21.17
    Gilead says first data on Nimbus NASH candidate are positive

    Gilead Sciences has the first proof-of-concept data for its novel drug...

';